Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

CVS Issues Revised Prior Authorization Forms

  |  Issue: June 2022  |  

CVS Caremark has issued revised prior authorization forms in response to ACR and provider concerns about administrative burden.

In July 2021, CVS Caremark changed its prior authorization forms for many biologic drugs, creating an increased administrative burden for rheumatology practices. The ACR received many complaints about the changes, which included new criteria around the evaluation of treatment efficacy for continuation of therapy requests. ACR leaders have had several conversations with CVS representatives and relayed these concerns. In April, CVS responded by issuing a streamlined version of the forms. 

ADVERTISEMENT
SCROLL TO CONTINUE

ACR is continuing to monitor this issue to ensure it is appropriately resolved and the burden on practices is reduced. We encourage members to contact [email protected] with any questions or concerns.

Related Articles

    The ACR Responds to CVS Caremark Prior Authorization Changes

    The ACR sent a letter to CVS Caremark detailing how recent updates to its prior authorization forms for many biologic drugs are increasing the paperwork burden for rheumatology practices and hurting patients’ timely access to treatment.

    Prior Authorization Is Under Review

    I just couldn’t believe it. Like all of you, I receive many requests to see patients urgently. And like all of you, I can’t possibly accommodate all of those requests. So I triage: I look through the referrals and try to differentiate patients who want to be seen from those who need to be seen….